GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

LigaChem Biosciences 141080.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

56,800

-2.74%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About LigaChem Biosciences

Its shares trade on KOSDAQ under the ticker 141080.KQ. It has been listed since 10 May 2013. In the fiscal year to 31 December 2025, it reported revenue of ₩141.55bn and a net loss of ₩74.28bn. At that date it held total assets of ₩701.81bn and shareholders' equity of ₩507.61bn.

LegoChem Biosciences, Inc. engages in the development, manufacture of medicines, medical devices and medical supplies. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2013-05-10. The firm principally involves in the development of new drugs, including antibiotics, anticoagulants, anticancer, antiplatelet, anti-inflammatory, as well as antibody-drug-conjugates (ADC), among others. The firm operates its business through technology transfer, joint and contact research and research services.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
10 May 2013
Employees
116

Leadership

Pay as last reported

  • Mr. Yong Ju KimChief Executive Officer, Director, since 2006
  • Mr. Se Jin ParkSenior Vice President, Director, since 2006
  • Mr. Yeong Rak ChoVice President, Director
  • Mr. Du Won ParkInternal Auditor
  • Dr. Rodrigo SotoChief Medical Officer
  • Mr. Rak Gyeong SongNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • LegoChem Biosciences Inc develops antibiotics and ADCs in Daejeon, KR.
  • The company has 116 employees focused on drug development in Health Care.
  • LegoChem Biosciences operates through technology transfer and joint research services.

Weaknesses

  • LegoChem Biosciences has no presence in the Financials sector or Real Estate.
  • The company's business is limited to Daejeon, Daejeon, KR, with no international expansion.
  • LegoChem Biosciences does not operate in the Consumer Discretionary segment.

Opportunities

  • LegoChem Biosciences can expand into the Information Technology sector for drug development.
  • The company can leverage its Life Sciences Tools & Services expertise in the Health Care industry.
  • LegoChem Biosciences may grow by entering the Materials sector for medical supplies.

Threats

  • LegoChem Biosciences faces competition from other Health Care firms in Daejeon.
  • The company's reliance on Daejeon, Daejeon, KR may limit market access.
  • LegoChem Biosciences could face regulatory challenges in the Life Sciences Tools & Services industry.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.